How to Help Your Patients Save Money on Neupro: A Provider's Guide to Savings Programs

At a list price of approximately $806 per month — with no generic alternative available in the United States as of 2026 — Neupro (rotigotine) is one of the more cost-challenging medications in neurology practice. Adherence to Neupro is directly tied to patients' ability to afford it consistently. As the prescriber, you are in a uniquely powerful position to connect patients with savings programs they may not know exist, to advocate for insurance coverage, and to document clinical necessity in a way that maximizes their access. This guide covers every available mechanism for reducing Neupro costs for your patients.

Understanding the Cost Landscape

Before connecting patients with savings programs, it helps to understand the financial landscape by insurance type:

• Commercially insured patients: Approximately 83% pay $0–$100/month with insurance. The UCB Neupro Patient Savings Card can bring copays to as low as $10/month.
• Medicare Part D patients: 68% pay $0–$100/month; 32% pay approximately $190/month. The UCB savings card cannot be used with Medicare, but other programs apply.
• Medicaid patients: Typically pay $4.90–$9.80/month; some states have lower or zero copays.
• Uninsured patients: Face full retail cash price of $873–$1,095+/month. Patient Assistance Programs (PAPs) are critical for this group.

Program 1: UCB Neupro Patient Savings Card — For Commercially Insured Patients

The UCB Neupro Patient Savings Card is the most impactful tool for commercially insured patients. Key details prescribers should know and communicate:

• As little as $10 per 30-day supply
• Maximum savings: $125 per fill, $1,500 per calendar year
• Registration: neupro.com/parkinsons-disease/neupro-savings-card | Phone: 1-855-841-0263
• Eligibility: Commercially insured patients only — NOT available for Medicare, Medicaid, VA, DOD, TRICARE
• Card expires at end of each calendar year — patients must re-enroll annually

Best practice: Print the savings card URL on your patient handout or have front-desk staff mention it to every new Neupro patient. Many eligible patients never use it simply because they were not told it existed.

Program 2: UCB Patient Assistance Program — For Uninsured/Underinsured Patients

UCB's Patient Assistance Program (PAP) provides Neupro at reduced or no cost to patients who lack adequate insurance coverage. General eligibility thresholds:

• Individual income under approximately $40,000/year
• Couple/household income under approximately $60,000/year
• No or inadequate insurance coverage
• Contact: 1-877-785-8906 | ucbCARES® line: 1-844-599-CARE (2273)

The application typically requires your office's prescription, the patient's income documentation, and proof of insurance denial or uninsured status. Your staff or a social worker can assist patients in completing applications.

Program 3: PAN Foundation — For Medicare Patients and Others With Cost-Sharing Challenges

The Patient Advocate Network (PAN) Foundation offers premium and cost-sharing assistance for qualifying patients — including those on Medicare who cannot benefit from the manufacturer's savings card. PAN Foundation assistance is income-based and disease-specific. Patients can apply at panfoundation.org or call 1-866-316-7263. Having your office help the patient initiate the application significantly increases the completion rate.

Program 4: UCB's Patch Partnership Program — Onboarding Support and Adherence

UCB's Patch Partnership Program™ provides newly initiated Neupro patients with onboarding materials, adherence support, and ongoing educational resources. While not a cost savings program per se, better patient education and support leads to fewer dosing errors and missed refills — which indirectly reduces waste and improves the cost-effectiveness of therapy. Encourage patients to sign up through the ucbCARES® line or the Neupro website.

Insurance Strategy: Prior Authorization and Step Therapy

Prior authorization (PA) is one of the primary access barriers for Neupro. When Neupro is approved by insurance under PA, the patient's out-of-pocket cost is often dramatically lower than the cash price — sometimes $0–$50/month versus $873+. The economics of getting the PA approved are therefore enormous. Key documentation that supports a successful PA:

• Documented diagnosis (ICD-10 code G20 for Parkinson's disease; G25.81 for RLS)
• Prior trial dates and outcomes for pramipexole and ropinirole (required by most step therapy protocols)
• Clinical rationale for patch specifically: dysphagia, nausea/GI intolerance with oral agents, motor fluctuations requiring continuous dopaminergic stimulation
• Duration requested: 1 year, with intent to continue if effective

If denied: Request a peer-to-peer review call. Neurologist-to-neurologist clinical review calls have a high approval rate for complex movement disorder cases when the clinical rationale is well articulated.

Medicare Strategy: Open Enrollment Plan Optimization

For Medicare patients, the specific Part D plan they are enrolled in can make a $100–$200/month difference in their Neupro cost. Consider including Medicare plan comparison as part of your annual care for Parkinson's patients:

1. At each annual visit, confirm the patient's current Part D plan and what they are paying for Neupro.
2. If out-of-pocket is high ($150+/month), advise the patient (or their caregiver) to use the Medicare Plan Finder at medicare.gov to compare Neupro coverage across plans during Open Enrollment (October 15 – December 7).
3. Help identify if the patient qualifies for Medicare Extra Help (Low Income Subsidy) — patients with limited income and assets may qualify for significantly reduced Part D cost-sharing.

Mail-Order Pharmacy for 90-Day Supply Savings

Most insurance plans offer lower per-dose cost when filling 90-day supplies via mail-order versus 30-day retail. For a brand-name drug like Neupro, this can reduce cost by $20–$60 per month. When prescribing, consider writing for 90-day quantities and directing patients to their plan's mail-order pharmacy. Mail-order also improves supply reliability, reducing the risk of patients running out before their local pharmacy gets restocked.

Practice Systems: Building Savings Outreach Into Your Workflow

The most effective practices have systematic approaches rather than relying on ad hoc counseling:

• New patient intake: Include a Neupro savings card handout with every new Neupro prescription
• Annual visit: Confirm insurance type and current Neupro copay; identify patients paying >$100/month for additional support
• Social work or care coordinator: Assign a team member to help patients apply for UCB PAP or PAN Foundation when appropriate
• Refill alerts: If a patient has not refilled their Neupro within 32 days, flag it in your system — missed refills may signal a cost or access issue

The Bottom Line

The cost of Neupro is a solvable problem for most patients — but only if they know about and access the right programs. The UCB savings card, PAP, PAN Foundation, Medicare plan optimization, and prior authorization approval can collectively make Neupro affordable for almost any patient. Your role as the prescriber — particularly in documenting clinical necessity and initiating the prior authorization process — is the most powerful lever in this system. For patients who struggle to find Neupro, recommend medfinder for providers and share the patient savings guide with your patients directly.